SKYE
$0.68-0.04 (-5.28%)
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
Intraday
Recent News
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
Skye Bioscience Inc (SKYE) reports promising weight loss results and strategic R&D collaborations, despite challenges in dosing and delivery.
Companies Like Skye Bioscience (NASDAQ:SKYE) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience
Halozyme Therapeutics (HALO) shares are in focus after the company entered a non exclusive global collaboration with Skye Bioscience in December 2025 to apply its ENHANZE drug delivery technology to a potential obesity treatment. See our latest analysis for Halozyme Therapeutics. The Skye Bioscience agreement lands at a time when Halozyme’s share price has picked up momentum, with a 15.47% 1 month share price return and 12.16% 3 month share price return. The 1 year total shareholder return of...
Skye Bioscience Inc (SKYE) Q3 2025 Earnings Call Highlights: Promising Study Results and ...
Skye Bioscience Inc (SKYE) reports encouraging phase 2A study outcomes but faces increased R&D expenses and net loss.
Why Skye Bioscience (SKYE) Is Down 51.0% After Releasing Phase 2a Nimacimab Trial Results and What's Next
Skye Bioscience recently held a special call to discuss the topline results from its Phase 2a clinical trial evaluating Nimacimab as both a monotherapy and in combination therapy. This announcement is particularly significant, as topline clinical trial data plays a critical role in shaping the outlook for clinical-stage biopharmaceutical companies. We'll examine how the release of Phase 2a topline data for Nimacimab shapes Skye Bioscience's investment narrative and future prospects. This...